PHOENIX, May 29, 2018 (GLOBE NEWSWIRE) -- Dr. Mark Day, president and chief executive officer of Bioasis Technologies Inc. (OTCQB:BIOAF) (TSX.V:BTI) (“the Company”), recently spoke with “Stock
Day” host Everett Jolly about the company’s undertakings in the neuroscience research and development field.
Bioasis Technologies Inc. is a biopharmaceutical company carrying out research and development of medications to treat a variety
of serious neurological disorders. This includes conditions such as brain cancers and neurodegenerative diseases, such as
Parkinson’s and Progressive Super Nuclear Palsy (PSNP), complex disorders with no definitive course of treatment.
Dr. Mark Day’s academic background in neuroscience and professional experience with research and business development made him
an ideal candidate to take over the company in April 2017. “I’m excited to drive a company like Bioasis forward, because I think it
has tremendous potential.” Dr. Day explains further that a major factor in wanting to join Bioasis was his desire to actually make
an effective medicine, rather than just conducting research.
Bioasis has developed a proprietary brain delivery technology called the xB3 TM platform, which is designed to
deliver therapeutics across the blood-brain barrier (BBB). Dr. Day says the purpose of the BBB is to prevent blood-borne diseases
and toxins from getting in to the brain, but it can also prevent treatments from getting to the brain. The purpose of the company’s
xB3 platform technology is to bypass the BBB and to make life-saving therapies brain-penetrant. The
xB3 platform has shown high efficacy in its ability to shuttle molecules across the BBB and reach its targets
within the brain.
Bioasis recently announced the Company’s intention to list on the NASDAQ Exchange as well as a collaboration with WuXi Biologics to develop and manufacture xB3-001, the Company’s
lead investigational candidate to treat brain cancer.
The company is currently listed on the TSX Venture Exchange under the ticker symbol BTI and also trades on the OTCQB under the
ticker symbol BIOAF. The current share price is U.S. $0.48 per share.
To learn more about blood-brain barrier science, the company’s internal pipeline and business development strategies, listen to
the audio of the full interview at the link below.
https://upticknewswire.com/featured-interview-ceo-dr-mark-day-of-bioasis-technologies-inc-otcqb-bioaf/
About Bioasis Technologies, Inc.
Bioasis Technologies, Inc. is a biopharmaceutical company developing xB3, a proprietary platform technology for the
delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical
need, including brain cancers and neurodegenerative diseases. The in-house development programs at Bioasis are designed to develop
symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in
Richmond, British Columbia, Canada with offices in Guilford, Conn., USA.
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and,
consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect,"
"estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes,"
"predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These
forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially
from the expected results.
Contact:
Uptick Newswire, LLC
Dana Peters, Communications Director
602-441-3474
dana.uptick@gmail.com
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news
and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick
Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched
the Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the
company’s message board at https://investorshangout.com/
